We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current EAPI market cap is 280.6M. The company's latest EPS is EUR -1.9957 and P/E is -1.48.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 915.8M | 944.6M | 892.8M | 976.6M | 1.01B |
| Operating Income | -500k | -10.9M | -3.8M | -800k | -232.5M |
| Net Income | 2.5M | -6.3M | -8.1M | -15M | -189.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 1.58B | 1.6B | 1.62B | 1.74B | 1.61B |
| Total Liabilities | 558.6M | 611.7M | 606M | 625.9M | 684.7M |
| Total Equity | 1.02B | 989.3M | 1.02B | 1.11B | 927.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | 34.9M | 96.8M | 71.7M | 45M | 5.1M |
| Investing | -81.1M | -88.3M | -87.9M | -167.4M | -137.3M |
| Financing | 46.1M | -8.4M | 26.5M | 187.6M | 92.2M |
| Market Cap | 280.6M |
| Price to Earnings Ratio | -1.48 |
| Price to Sales Ratio | 0.28 |
| Price to Cash Ratio | 8.13 |
| Price to Book Ratio | 0.3 |
| Dividend Yield | - |
| Shares Outstanding | 95.05M |
| Average Volume (1 week) | 209.3k |
| Average Volume (1 Month) | 324.71k |
| 52 Week Change | -72.97% |
| 52 Week High | 12.97 |
| 52 Week Low | 2.26 |
| Spread (Intraday) | 0.02 (0.75%) |
| Company Name | Euroapi SA |
| Address |
15 rue traversiere paris, paris 75012 |
| Website | https://www.euroapi.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
